Peter Kaiser, MD, and Michael Singer, MD, discuss strategies choosing an anti-VEGF treatment based on patients’ personal needs, how to handle non-responders, and what do to when inflammation is a concern.

Peter Kaiser, MD, and Timothy Murray, MD, MBA, discuss the HAWK and HARRIER phase 3 studies evaluating the safety and efficacy of brolucizumab for wet AMD.

Peter Kaiser, MD, and Jeffrey Heier, MD, examine the findings of the Novartis-appointed Safety Review Committee’s independent assessment of post-marketing cases of inflammation following the approval of brolucizumab.